variables | S1PR1 | pSTAT3 | ||||||
---|---|---|---|---|---|---|---|---|
 | Negative | Positive | Total | P* | Negative | Positive | Total | P* |
Age, years | Â | Â | Â | Â | Â | Â | Â | Â |
 Mean (range) |  |  |  |  |  |  |  |  |
 <60 | 30 (48%) | 20 (49%) | 50 (49%) | 0.969 | 21 (50%) | 29 (48%) | 50 (49%) | 0.806 |
 ≥60 | 32 (52%) | 21 (51%) | 53 (51%) |  | 21 (50%) | 32 (52%) | 53 (51%) |  |
Sex | Â | Â | Â | Â | Â | Â | Â | Â |
 Male | 34 (55%) | 29 (67%) | 61 (59%) | 0.265 | 28 (67%) | 33 (54%) | 61 (59%) | 0.202 |
 Female | 28 (45%) | 14 (33%) | 42 (41%) |  | 14 (33%) | 28 (46%) | 42 (41%) |  |
Primary nodal disease | Â | Â | Â | Â | Â | Â | Â | Â |
 Nodal | 27 (44%) | 10 (24%) | 37 (36%) | 0.047†| 21 (50%) | 16 (26%) | 37 (36%) | 0.013†|
 Extranodal | 35 (56%) | 31 (76%) | 66 (64%) |  | 21 (50%) | 45 (74%) | 66 (64%) |  |
Primary UAT disease | Â | Â | Â | Â | Â | Â | Â | Â |
 Non-UAT | 55 (89%) | 28 (68%) | 83 (81%) | 0.010†| 39 (93%) | 44 (72%) | 83 (81%) | 0.009†|
 UAT | 7 (11%) | 13 (32%) | 20 (19%) |  | 3 (7%) | 17 (28%) | 20 (19%) |  |
Ann Arbor stage | Â | Â | Â | Â | Â | Â | Â | Â |
 I, II | 26 (42%) | 21 (51%) | 47 (46%) | 0.354 | 18 (43%) | 29 (48%) | 47 (46%) | 0.639 |
 III, IV | 36 (58%) | 20 (49%) | 56 (54%) |  | 24 (57%) | 32 (52%) | 56 (54%) |  |
IPI group‡ |  |  |  |  |  |  |  |  |
 Low (0–2) | 36 (61%) | 24 (65%) | 60 (63%) | 0.705 | 23 (59%) | 37 (65%) | 60 (63%) | 0.555 |
 High (3–5) | 23 (39%) | 13 (35%) | 36 (37%) |  | 16 (41%) | 20 (35%) | 36 (37%) |  |
B symptoms‡ |  |  |  |  |  |  |  |  |
 Absent | 46 (76%) | 31 (78%) | 77 (76%) | 0.809 | 36 (86%) | 41 (69%) | 77 (76%) | 0.059 |
 Present | 15 (24%) | 9 (22%) | 24 (24%) |  | 6 (14%) | 18 (31%) | 24 (24%) |  |
ECOG PS‡ |  |  |  |  |  |  |  |  |
 0, 1 | 54 (87%) | 32 (80%) | 86 (84%) | 0.336 | 36 (86%) | 50 (83%) | 86 (84%) | 0.745 |
 ≥2 | 8 (13%) | 8 (20%) | 16 (16%) |  | 6 (14%) | 10 (17%) | 16 (16%) |  |
LDH‡ |  |  |  |  |  |  |  |  |
 Normal | 25 (43%) | 18 (47%) | 43 (45%) | 0.681 | 16 (42%) | 27 (47%) | 43 (45%) | 0.668 |
 Elevated | 33 (57%) | 20 (53%) | 53 (55%) |  | 22 (58%) | 31 (53%) | 53 (55%) |  |
BM involvement‡ |  |  |  |  |  |  |  |  |
 Absent | 56 (90%) | 29 (78%) | 85 (86%) | 0.099 | 38 (95%) | 47 (80%) | 85 (86%) | 0.032†|
 Present | 6 (10%) | 8 (22%) | 14 (14%) |  | 2 (5%) | 12 (20%) | 14 (14%) |  |
Number of extranodal sites | Â | Â | Â | Â | Â | Â | Â | Â |
 0, 1 | 45 (73%) | 30 (73%) | 75 (73%) | 0.947 | 30 (71%) | 45 (74%) | 75 (73%) | 0.793 |
 ≥2 | 17 (27%) | 11 (27%) | 28 (27%) |  | 12 (29%) | 16 (26%) | 28 (27%) |  |
EBER‡ |  |  |  |  |  |  |  |  |
 Negative | 58 (94%) | 37 (95%) | 95 (94%) | 0.784 | 39 (93%) | 56 (95%) | 95 (94%) | 0.666 |
 Positive | 4 (6%) | 2 (5%) | 6 (6%) |  | 3 (7%) | 3 (5%) | 6 (6%) |  |
Hans classification‡ |  |  |  |  |  |  |  |  |
 GCB | 24 (40%) | 13 (33%) | 37 (37%) | 0.503 | 21 (53%) | 16 (27%) | 37 (37%) | 0.010†|
 Non-GCB | 36 (60%) | 26 (67%) | 62 (63%) |  | 19 (47%) | 43 (73%) | 62 (63%) |  |
pSTAT3 nuclear expression | Â | Â | Â | Â | Â | Â | Â | Â |
 Negative | 28 (45%) | 14 (34%) | 42 (41%) | 0.265 | - | - | - | - |
 Positive | 34 (55%) | 27 (66%) | 61 (59%) |  | - | - | - |  |
Total | 62 (100%) | 41 (100%) | 103 (100%) | Â | 42 (100%) | 61 (100%) | 103 (100%) | Â |